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Borreliaburgdorferievadescomplement-mediatedkillingbyinteractingwith complementregulatorsthroughdistinctcomplement
regulator-acquiring surface proteins (CRASPs). Here, we extend our analyses to the contribution of CRASP-4 in mediating
complement resistance of B. burgdorferi and its interaction with human complement regulators. CRASP-4 (also known as ErpC)
w a si m m o b i l i z e do n t om a g n e t i cb e a d sa n du s e dt oc a p t u r ep r o t eins from human serum. Following Western blotting, factor H
(CFH), CFH-related protein 1 (CFHR1), CFHR2, and CFHR5 were identiﬁed as ligands of CRASP-4. To analyze the impact of
native CRASP-4 on mediating survival of serum-sensitive cells in human serum, a B. garinii strain was generated that ectopically
expresses CRASP-4. CRASP-4-producing bacteria bound CFHR1, CFHR2, and CFHR5 but not CFH. In addition, transformed
spirochetes deposited signiﬁcant amounts of lethal complement components on their surface and were susceptible to human
serum, thus indicating that CRASP-4 plays a subordinate role in complement resistance of B. burgdorferi.
1.Introduction
Lyme borreliosis, caused by spirochetes of the Borrelia burg-
dorferi sensu lato complex, is the most prevalent vector-
borne anthropozoonosis in Eurasia and the United States
[1]. The ability of spirochetes to perpetuate their natural
vertebrate-tick infectious cycle spirochetes requires an array
of mechanisms to successfully colonize their tick vectors
and rodent reservoir hosts, survive in diverse environments,
and evade host innate and adaptive immune responses. Re-
cently, it has been shown that certain genospecies resist
complement-mediated killing of human serum, in particular
B. burgdorferi sensu stricto (hereafter referred to as B.
burgdorferi), B. afzelii, B. spielmanii,a n dB. bavariensis (for-
merly known as B. garinii OspA serotype 4 strains) [2–
5]. Elucidation of the underlying molecular mechanism(s)
of complement resistance among Lyme disease spirochetes
revealed that binding of the host complement regulators
factor H (CFH) and factor H-like protein 1 (FHL1) to the
bacterial surface directly correlates with serum resistance [3,
6–10]. In contrast, B. garinii, B. valaisiana,a n dB. lusitaniae
are highly susceptible to complement-mediated killing and
either do not bind, or bind inadequate levels of complement
regulators [2, 4, 10–12].
Complement plays a central role in the recognition
and elimination of invading microorganisms [13]. Upon2 Clinical and Developmental Immunology
activation of the initial steps of the complement cascade via
the classical, alternative, or lectin pathway, a C3 convertase
is generated which cleaves the central component C3 into
its reactive fragments C3a and C3b. The highly reactive C3b
fragmentcovalentlybinds tomolecules,proteins, andnearby
membranes,therebyleadingtoopsonizationoftheintruding
microorganisms. This initial step is necessary for clearance
of foreign microorganisms by phagocytosis, formation of
the C3 convertase, and assembly of both the C5 convertase
and the membrane attack complex (MAC). To protect host
cell surfaces from uncontrolled and continuous activation,
the complement system is well balanced and ﬁnely tuned by
diverse ﬂuid phase and membrane-anchored negative regu-
lators[14–16].CFHandFHL1arethekeyﬂuidphaseregula-
torsofthehumanalternativepathwayandactascofactorsfor
factor-I-mediated inactivation of C3b to iC3b, compete with
factor B for binding to C3b, and ﬁnally support the dissoci-
ation (decay-accelerating activity) of the alternative pathway
C3 convertase, C3bBb [16–20] .C F Hi sc o m p o s e do f2 0
individuallyfoldingproteindomainstermedshortconsensus
repeats (SCRs) of which the four N-terminal-located SCRs
exhibit the complement regulatory activity. FHL1 is a 42kDa
glycoprotein, comprised of the seven amino-terminal SCRs
of CFH plus four unique amino acids at the C-terminus [17,
20]. The human CFH family includes additional “factor H-
related”proteins(CFHR),namely,CFHR1,CFHR2,CFHR3,
CFHR4A, CFHR4B and CFHR5, all of which are encoded
by distinct genes located in the regulators of complement
activation (RCA) gene cluster on human chromosome 1
[21–23].TheC-terminalSCRdomainsoftheCFHRproteins
share high degrees of similarity to the C-terminal surface
binding region of CFH, that is, SCRs 18–20 [16, 24]. The
CFHR1 protein consists of ﬁve SCRs and exists in two gly-
cosylated forms, the 37kDa CFHR1α protein with one and
the 43kDa CFHR1β protein with two carbohydrate chains
attached [25, 26]. CFHR1 is a complement regulator that
blocks C5 convertase activity as well as assembly and mem-
brane insertion of the terminal membrane attack complex
[27]. CFHR2 is composed of four SCRs and is found in
plasma as a nonglycosylated 24kDa form (CFHR2) and a
glycosylated 29kDa form (CFHR2α)[ 28]. The function(s)
of CFHR2 is as still unclear. The 65kDa CFHR5 protein
is comprised of 9 SCRs and displays cofactor activity for
factor-I-mediated inactivation of C3b [29, 30]. CFHR5 also
inhibits the activity of the ﬂuid phase C3 convertase.
Lyme disease Borreliae camouﬂage themselves with host-
derived complement regulators through three groups of ge-
netically unrelated genes/proteins collectively termed com-
plement regulator-acquiring surface proteins or “CRASPs”
[3, 9, 31–35]. All investigated serum-resistant borrelial
strains so far express the CRASP-1 protein in diﬀerent com-
binations with CRASP-2, CRASP-3, CRASP-4, and/or
CRASP-5. Based on the binding proﬁle for complement reg-
ulators, CRASPs expressed by B. burgdorferi are divided into
CFH and FHL1 binding proteins that do not bind CFHR1
(CRASP-1/CspA and CRASP-2/CspZ) and molecules that
interact with CFH and CFHRs, but not FHL1 (CRASP-
3/ErpP, and CRASP-4/ErpC, CRASP-5/ErpA) [9, 34, 36–
39]. The potential of single CRASP-molecules in mediating
complement resistance of B. burgdorferi s.s. is still under
debate. Borrelial strains lacking functional CRASP-1 and
CRASP-2 are highly susceptible to complement-mediated
killing, and complementation with the respective CRASP
encoding genes restores the serum-resistant phenotype [31,
40–42]. The contributions of the CFH and CFHR-binding
CRASP-3 and CRASP-5 proteins in facilitating complement
resistanceofBorreliaearedisputed.Heterologousproduction
of either CRASP-3 or CRASP-5 in a B. garinii strain lacking
all functional CRASP molecules failed to convert the serum-
sensitive phenotype of the wild-type strain [39]. In contrast,
Kenedy and Akins have shown that CRASP-3 and CRASP-
5 produced in a CRASP-1 deletion strain lead to increased
survival in human serum as compared to a serum-sensitive
strain lacking CRASP-1 [43].
In the present studies, we extended our previous inves-
tigations on the CFH- and CFHR1 binding capacity of
CRASP-4/ErpC protein to additional proteins derived from
humanserumandtheircontributionstoconveycomplement
resistance. To this end, a B. garinii strain that ectopically
produced CRASP-4 was generated by transformation with a
shuttle vector harboring the CRASP-4 encoding erpC gene,
then the transformed strain was assayed for (i) the ability to
bind human complement regulators, (ii) surface deposition
of complement activation products, and (iii) survival in
human serum. Using recombinant CRASP-4, two additional
members of the human CFH protein family, CFHR2 and
CFHR5, were identiﬁed as novel ligands for CRASP-4 of B.
burgdorferi whereby CFHR2 showed stronger binding ca-
pacity for CRASP-4 as compared to CFHR1 and CFHR5.
However, borrelial cells producing CRASP-4 on their surface
did not bind CFH. Upon incubation in human serum,
large amounts of activated complement components were
deposited onto the surfaces of CRASP-4 producing cells and
the bacteria did not survive. This suggests that binding of
CFHR1, CFHR2, and CFHR5 is not suﬃcient to protect
spirochetes from complement-mediated bacteriolysis once
complement is activated.
2.MaterialandMethods
2.1. Bacterial Strains and Culture Conditions. B. burgdorferi
strains LW2 (skin isolate, Germany), B. garinii isolate G1
(CSF isolate, Germany), B. garinii transformants G1/pKFSS1
as well as G1/pCRASP-4 were grown at 33◦Cf o r2t o4d a y s
tomidexponentialphase(1 ×107 to 5 ×107 spirochetes/mL)
as described previously [39]. Escherichia coli DH5α used
for cloning experiments and protein expression was grown
at 37◦C in yeast tryptone broth, supplemented with the
appropriate antibiotics.
2.2. Human Sera and Polyclonal and Monoclonal Antibodies.
Normal human serum (NHS) obtained from 20 healthy
human blood donors without known history of spirochetal
infections was used as a source of complement regulators.
The study and the respective consent documents were
approved by the ethics committee at the Goethe University
ofFrankfurt(controlnumber160/10).Allblooddonorspro-
vided written, informed consent.Clinical and Developmental Immunology 3
Table 1: Oligonucleotides used in this study.
Oligonucleotide Sequence (5 –3 )a Use in this work
ErpC 5nc(+) GTTGTATGTGTTTTGAAGCTTTTAGTAATGAGCAGGGC Cloning in pKFSS1 and ampliﬁcation of erpC
HindIII
ErpC 3nc(−) CGATCTCTCCTGTATTTTAAGCTTCTATTTTAAATTTTTCTTAAG Cloning in pKFSS1 and ampliﬁcation of of erpC
HindIII
aadA + NdeI CATATGAGGGAAGCGGTGATC Ampliﬁcation of aadA gene
aadR + AatII GACGTCATTATTTGCCGACTACC Ampliﬁcation of aadA gene
Fla6 AACACACCAGCATCGCTTTCAGGGTCT Ampliﬁcation of ﬂaB gene
Fla7 TATAGATTCAAGTCTATTTTGGAAAGCACCTA Ampliﬁcation of ﬂaB gene
aSequences of speciﬁc restriction endonuclease recognition sites are underlined.
A polyclonal anti-CFH antiserum was utilized to detect
human CFH, CFHR1, and CFHR2 (Merck Biosciences,
Bad Soden, Germany and Complement Technology, Tyler,
TE). Rabbit polyclonal anti-CFHR1 antibody or monoclonal
antibody JHD 7.10 was used for detection of CFHR1 and
CFHR2 and CFHR5 [39]. The goat anti-human C3 and C6
antibodieswerepurchasedfromCalbiochem,andthemono-
clonalanti-humanC5b-9antibodyrecognizingtheMACwas
obtained from Quidel (San Diego, CA). MAb L41 1C11 was
used to detect the periplasmic FlaB protein. For analyzing
surface-exposedCRASP-4,arabbitpolyclonalantiserumthat
recognizes CRASP-4 and CRASP-5 was used [44, 45].
2.3. Expression of Recombinant CFHR1, CFHR2, and CFHR5.
RecombinantCFHR1wasexpressedinSpodopterafrugiperda
Sf9 insect cells infected with recombinant baculovirus. The
cloning of various deletion constructs, expression, and
puriﬁcation have been described previously [38].
The full length CFHR2 cDNA was cloned into pPICZαB
(Invitrogen), and the protein was expressed in the yeast
Pichia pastoris strain X33 according to standard protocols
[39]. The full length CFHR5 cDNA was cloned into pBSV-
8His and expressed in the baculovirus system as described
[46]. All expressed His-tagged recombinant proteins were
puriﬁedbyNi2+ chelateaﬃnitychromatographyasdescribed
[46].
2.4. Expression of Recombinant CRASP-4. The construction
of vector pBLS528 used for the production of amino-ter-
minallypolyhistidine-taggedCRASP-4(ErpC)wasdescribed
previously [47]. The erpC encoding sequence of B. burgdor-
feri strain LW2 is identical to the sequence of the erpC gene
of B. burgdorferi type strain B31.
Expression of recombinant CRASP-4 protein was in-
duced in DH5α at an OD600 of 0.6 by the addition of
0.2mM IPTG. Following incubation for 4h at room tem-
perature, cells were centrifuged (5000g, 20min, 4◦C) and
subsequently suspended in lysis buﬀer (300mMNaCl,
56mMNaH2PO4 pH 8, and 10mM Imidazole) containing
50mg/mL lysozyme. Bacterial cells were lysed by 6 rounds of
sonication for 30sec using a Branson B-12 soniﬁer (Heine-
mann, Schw¨ abisch Gm¨ und, Germany). After centrifugation
(14000g, 20min, 4◦C), supernatants were ﬁltered through
0,45μm ﬁlters and stored at −20◦C for later puriﬁcation via
aﬃnity chromatography.
2.5. Serum Incubation with Magnetic Beads Coated with
His-Tagged CRASP-4 Protein. Puriﬁed CRASP-4 (20μg) was
incubatedwith50μLofmagneticbeads(DynabeadsTALON,
Invitrogen Dynal AS, Oslo, Norway) for 10min at room
temperature as recommended by the manufacturer. After
four wash steps with phosphate buﬀer (50mM phosphate,
300mMNaCl, 0.01% Tween 20), histidine-tagged proteins
coupled onto beads were incubated with NHS for 1h on
ice. After extensive washing with phosphate buﬀer, bound
proteins were eluted with 50μL of 100mM glycine-HCl
(pH 2.0) for 15min. The eluate and the last wash fraction
were separated by 12.5% SDS-PAGE under nonreducing
conditions followed by silver staining.
2.6. Construction of Shuttle Vectors. To allow ectopic expres-
sion of CRASP-4 by the serum-sensitive B. garinii strain G1,
a shuttle vector was generated by using plasmid pKFSS1,
a streptomycin-resistant derivative of pBSV2 [48]. The
CRASP-4encodingerpCgeneplusitsnativepromotorregion
was ampliﬁed from B. burgdorferi strain LW2 by PCR using
primers containing the respective restriction sites and then
sequenced (Table 1). The sequence of the erpC gene of B.
burgdorferi strain LW2 is identical to that of B. burgdorferi
type strain B31. Amplicons were hydrolyzed with HindIII
and subsequently cloned into pKFSS1 at the corresponding
restriction site, yielding shuttle vector pCRASP-4. The
inserted sequence was subjected to nucleotide sequencing to
verify that no mutations had been introduced during PCR
and cloning procedures.
2.7. Transformation of Serum-Sensitive B. garinii. The non-
infectious, serum-sensitive B. garinii strain G1 was grown
in BSK medium and harvested at midexponential phase (5
× 107 to 1 × 108 cells/mL). Electrocompetent cells were
prepared and transformed as described previously [39]. For
selectionoftransformants,cellsweredilutedinto100mlBSK
medium containing 20μg/mL streptomycin, then 200μL
aliquots were transferred into 96-well plates (Corning). After
four to six weeks of incubation at 33◦C, wells were evaluated
for growth by color change of the medium and by dark-ﬁeld
microscopy for the presence of motile spirochetes. Several
clones were expanded in 1mL fresh BSK medium containing
streptomycin (20μg / m L )f o r7t o1 4d a y s .T r a n s f o r m e d
bacteria were then maintained in BSK medium containing
20μg/mL streptomycin.4 Clinical and Developmental Immunology
2.8. PCR Analysis of Transformed Borrelial Cells. Strepto-
mycin-resistant clones of transformed B. garinii were char-
acterized by PCR ampliﬁcation of the introduced erpC gene
and the recombinant plasmids streptomycin resistance gene
(aadA) using speciﬁc primers (Table 1). The native B. garinii
ﬂaBgenewasalsoampliﬁedviaPCRasapositivecontrol.Ten
microliter aliquots of bacterial cultures grown to midexpo-
nential phase were used for direct PCR. PCR was carried out
for 25 cycles using the following parameters: denaturation at
94◦Cfor1min,annealingat50◦Cfor1min,ande xt ensionat
72◦C for 1min. Reaction products were separated by agarose
gel electrophoresis, and DNA was visualized by ethidium
bromide staining and ultraviolet light.
2.9. SDS-PAGE, Western Blot, and Ligand Aﬃnity Blot Analy-
sis. Bacterial cell lysates were subjected to 10% Tris/Tricine-
SDS-PAGE under reducing conditions and samples obtained
by serum adsorption (last wash and eluate fractions) were
separated by SDS-PAGE under nonreducing conditions as
previously described [34].
For ligand aﬃnity blot analysis, membranes were incu-
bated for 1h with normal human serum. After four wash-
ings with TBS containing 0,2% Tween20, membranes were
incubated for 1h with either a polyclonal goat CFH anti-
serum, polyclonal anti-CFHR1 antiserum that recognizes
CFHR1, CFHR2, and CFHR5 and CFH or mAb JHD 7.10
which recognizes all three CFHRs but not CFH [38, 39, 49].
Following four washings with TBS containing 0,2% Tween
20, membranes were incubated with an appropriate perox-
idase-conjugated secondary antibody for 1h. Detection of
bound proteins was performed using 3,3 ,5,5  -tetrameth-
ylbenzidine (TMB) as a substrate.
ForWesternblotanalysis,membraneswereincubatedfor
1h at room temperature with antisera recognizing CRASP-
4/ErpC and CRASP-5/ErpA (αCRASP-4), CFH, CFHR1,
or FlaB (L41 1C11). Following four wash steps with
TBS containing 0,2% Tween20, membranes were probed
with appropriate peroxidase-conjugated secondary antisera
(Dako, Glostrup, Denmark) for 60 min at room temperature
and bound antibodies were detected using TMB.
2.10. ELISA. Microtiter plates (Nunc-Immuno Module)
werecoatedwithCRASP-4(5μg/mL)overnightat4◦C.Mic-
rotiter plates were washed with PBS containing 0.1% Tween
20andtreatedfor1hatRTwithblockingbuﬀer(AppliChem
GmBH, Darmstadt, Germany). After washing, equimolar
amounts (33μM) of CFH, CFHR1, CFHR2, or CFHR5 were
added and incubated for 1h at RT. Thereafter, the wells were
washed and bound CFH or CFHR proteins were detected
with either goat CFH polyclonal antiserum or MAb JHD
7.10, which reacts with all three CFHRs [39, 49]. After wash-
ing, bound proteins were identiﬁed using appropriate sec-
ondary horseradish peroxidise-coupled antisera. Detection
was performed with 1,2-phenylenediamine dihydrochloride
as a substrate (OPD, DakoCytomation, Glostrup, Denmark)
and absorbance was measured at 490nm.
2.11. In Situ Protease Accessibility Experiments. Viable Bor-
reliae were gently washed and resuspended in 500μL PBS
to obtain a density of 8 × 105/μL. Subsequently, proteinase
K and trypsin (Sigma-Aldrich, Deisenhofen, Germany)
were separately added to a ﬁnal concentration of 25 and
100μg/mL, respectively. Intact spirochetes without protease
treatment served as a control. Following incubation for
2h at room temperature, proteinase K and trypsin were
inactivated by addition of phenylmethylsulfonyl ﬂuoride
(Sigma-Aldrich) (50mg/mL in isopropanol). Cells were then
washed gently twice with PBS-5mMMgCl, resuspended
in 20μL of the same buﬀer, then lysed by sonication 5
times for 30sec using a Branson B-12 soniﬁer (Heinemann,
Schw¨ abisch Gm¨ und, Germany). Aliquots were separated us-
ing Tris/Tricine-SDS-PAGE as described above.
2.12. Serum Adsorption Assay. To assess binding of serum
proteins to viable borrelial cells, a serum adsorption assay
w a se m p l o y e da sd e s c r i b e dp r e v i o u s l y[ 7, 50]. Brieﬂy,
borrelial cells (1 × 109 cells) grown to midexponential
phase were washed and subsequently resuspended in 750μL
NHS supplemented with 34mM EDTA (pH 8.0) to avoid
complementactivation.After1hincubationandfourwashes
with PBS containing 0.01% Tween 20, proteins bound to the
cells surface were eluted with 100mM glycine-HCl (pH 2.0)
for 15min. Cells were removed by centrifugation at 14000g
for10minat4◦C,andthesupernatantandthelastwashwere
separated by SDS-PAGE under nonreducing conditions and
analyzed by Western blotting as described above.
2.13. Serum Susceptibility Testing. Serum susceptibility of
B. garinii isolate G1, G1/pKFSS1, and G1/pCRASP-4 was
assessed by a growth inhibition assay as described previously
[3, 42]. Brieﬂy, aliquots (1.25 × 107 cells) of highly motile
spirochetes were diluted into ﬁnal volumes of 100μLf r e s h
BSK medium, which contains 240μg/mL phenol red. As
bacteria grow in BSK, the medium acidiﬁes and the pH
indicator dye turns from red to yellow. One hundred micro-
liters of NHS or 100μL heat-inactivated NHS was added
to each aliquot of bacteria. Bacteria were then incubated in
96-well microtiter plates for 8 days at 33◦C. For controls,
aliquots of bacteria were also incubated with 100μLB S K
medium instead of NHS. Bacterial growth was monitored
daily by measuring the ratio of culture medium absorbance
at 562 versus 630nm, using an ELISA reader (PowerWave
HT; Bio-Tek Instruments, Winooski, VT). For calculation of
the growth curves the Gen5 software (Bio-Tek Instruments,
Winooski, VT) was used. Each experiment was conducted at
least three times, and means ± SD were calculated.
2.14. Immunoﬂuorescence Assay. Spirochetes grown to mid-
exponential phase were harvested by centrifugation (5000g,
30min), washed, and resuspended in veronal buﬀered saline
(VBS, supplemented with 1mMMg2+,0 . 1 5m MC a 2+,a n d
0.1% gelatin, pH 7.4).
For detection of deposited complement components on
the bacterial surface, spirochetes (6 × 106) were incubated in
25%NHSand,asacontrol,in25%heat-inactivatedNHSfor
30min at 37◦C with gentle agitation as previously described
[3, 42].Clinical and Developmental Immunology 5
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Figure 1: Identiﬁcation of serum proteins that bind to recombinant CRASP-4. Recombinant, polyhistidine-tagged CRASP-4 was immo-
bilized onto magnetic beads and incubated with NHS. Uncoated beads were also treated under the same conditions and used as a control to
identify nonspeciﬁc binding of serum proteins. After extensive washing, bound proteins were eluted with 100mM glycine-HCl (pH 2.0) and
the eluate fractions were separated by SDS-PAGE under nonreducing conditions. (a) Silver stain of a gel loaded with puriﬁed polyhistidine-
tagged CRASP-4 (1μg), eluate fraction of the uncoated beads, and the ﬁnal wash and eluate fraction of CRASP-4-coated beads. (b) Western
blot analysis of the eluate fraction of CRASP-4-coated beads using a polyclonal anti-CFH or a polyclonal anti-CFHR1 antiserum. Mobilities
of molecular mass standards are indicated to the left.
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Figure 2: CRASP-4 binds distinct complement proteins. Binding of
equimolar amounts of CFH, CFHR1, CFHR2, and CFHR5 (33μM)
to immobilized CRASP-4 (5μg/mL) was analyzed by ELISA. Bound
CFH or CFHR proteins were detected with either goat CFH
polyclonal antiserum or mouse CFHR1 monoclonal antiserum
(JHD 7.10), which reacts with all three CFHRs. Data represent the
means and standard errors from three separate experiments.
In order to detect surface-exposed proteins, polyclonal
rabbit anti-CRASP-4 antiserum (1:50 dilution) was added
to the cells for 1h at 37◦C with gentle agitation. After two
washes with PBS containing 1% BSA, 10μL aliquots of the
cell suspensions were spotted on glass slides and allowed to
air-dry overnight (= unﬁxed cells). Slides were then ﬁxed
in methanol for 10min and air-dried for 1h, followed by
incubation with an adequate Alexa 488-conjugated antibody.
Slides were then gently washed four times with PBS and
mounted on ProLong Gold antifade reagent (Molecular
Probes) containing DAPI before being sealed. Slides were
visualized at a magniﬁcation of ×1,000 using an Olympus
CX40 ﬂuorescence microscope mounted with a DS-5Mc
charge-coupled device camera (Nikon).
As a control, periplasmic FlaB was also investigated using
unﬁxed as well as ﬁxed spirochetes as described previously
[39].
3. Results
3.1. CRASP-4 Interacts with Human Complement Regulators.
To identify serum components that bind to CRASP-4, the
puriﬁed his-tagged protein was immobilized on magnetic
beads. Following incubation with NHS, beads were exten-
sively washed and bound serum proteins along with CRASP-
4w e r ee l u t e d .T h ee l u a t ef r a c t i o no ft h eC R A S P - 4 - c o a t e d
beads and eluate fraction of uncoated beads as well as the
ﬁnal wash were separated by SDS-PAGE and analyzed by
silver staining (Figure 1(a)). A bulk of proteins in the 60 to
80kDa range was detected in the eluate fractions of CRASP-
4-coated beads and also in the eluate fraction of uncoated
beads. In the eluate fraction of uncoated beads and in the
ﬁnal wash fraction but not in the eluate fraction of CRASP-
4-coated beads, a 55kDa protein was found. In contrast,6 Clinical and Developmental Immunology
proteins with apparent molecular masses of 60, 38, 35,
29, 25 and 22kDa were detected only in the eluate fraction
of CRASP-4-coated beads.
To identify the serum proteins bound to the recombinant
CRASP-4protein,Westernblotanalysiswasperformedusing
speciﬁc antisera. All serum proteins bound to CRASP-4 react
with the polyclonal anti-CFHR1 antiserum that recognizes
the two diﬀerent glycosylated forms of CFHR1 (CFHR1α
and CFHR1β) and CFHR2 (CFHR2, and CFHR2α)a sw e l l
as CFHR5 (Figure 1(b)). By using a polyclonal anti-CFH
antiserum, four signals corresponding to CFHR1α (35kDa)
and CFHR1β (32kDa) and CFHR2 (25kDa) and CFHR2α
(22kDa) could be detected. The 150kDa CFH protein
was not detected by either silver staining or Western blot,
indicating that CRASP-4 did not bind CFH under these
experimental conditions. The protein with an apparent mass
of 22kDa represents CRASP-4. Taken together, CRASP-4
binds to human CFH protein family members, including
CFHR1, CFHR2, and CFHR5.
Next, binding of recombinant CRASP-4 to each of the
three identiﬁed human serum proteins was analyzed by ELI-
SA (Figure 2). CRASP-4 was immobilized onto a microtiter
plate and binding of puriﬁed recombinant CFHR1, CFHR2,
CFHR5 and serum-puriﬁed CFH was assayed. All three
CFHR proteins, that is, CFHR1, CFHR2, and CFHR5 as well
as CFH bound to the immobilized CRASP-4 protein, with
the greatest apparent aﬃnity being for CFHR2.
3.2. Generation of a CRASP-4-Expressing B. garinii Strain.
Dependingonthegeneticcomposition,allserum-resistantB.
burgdorferi isolates analyzed to date express at least two dis-
tinct CRASP molecules. In order to assess the contribution
of an individual CRASP molecule in mediating complement
resistance, the serum-sensitive B. garinii strain G1 (does
not express any of these CRASP proteins during laboratory
cultivation) was chosen for functional analyses of the
CRASP-4 protein [34]. B. garinii G1 was transformed with
the plasmid pCRASP-4, which harbors the entire CRASP-4
encoding erpC gene under the control of its native promotor,
and with the empty shuttle vector pKFSS1. Transformants
selected by the microdilution method were conﬁrmed by
PCR ampliﬁcation of the CRASP-4 encoding erpC and
the streptomycin resistance aadA gene (Figure 3(a)). Strain
G1/pCRASP-4 yielded an amplicon corresponding to erpC,
whereas the control strains G1 and G1/pKFSS1 did not.
The aadA gene of the shuttle vectors was detected in
the transformed cells, but not in the wild-type strain G1.
Production of CRASP-4 in B. garinii G1 was veriﬁed through
analysis of cell lysates from the CRASP-4 expressing cells
and the nonexpressing control strains G1 and G1/pKFSS1
(Figure 3(b)).
3.3. Surface Exposure of CRASP-4 in B. garinii G1/pCRASP-4.
CRASP-4 and other members of the Erp paralogous protein
family are surface exposed proteins [44]. To conﬁrm surface-
exposure of these proteins in transformed B. garinii, intact
spirochetes were treated with proteinase K and trypsin,
followed by ligand aﬃnity blotting of borrelial lysates
(Figure 3(c)). Analyses of protease-treated cells revealed that
CRASP-4 was highly susceptible to digestion by proteinase K
butnottrypsin,aspreviouslydescribedforthenativeprotein
[44]. Surface localization of CRASP-4 was also examined
by immunoﬂuorescence microscopy using live bacteria and
polyclonal antibodies speciﬁc for CRASP-4 [44]. To avoid
damage to the fragile borrelial outer membrane, intact
bacteria were incubated with antibodies before ﬁxation onto
glass slides and sealed with mounting medium containing
the DNA-binding dye DAPI. As shown in Figure 3(d),
CRASP-4 positive cells showed a strong ﬂuorescent staining,
thus indicating that CRASP-4 was localized on the outer
membrane. Integrity of the fragile borrelial outer membrane
was conﬁrmed by the lack of binding of antibodies directed
against the periplasmic ﬂagellar protein FlaB (Figure 3(d)).
Control strains G1 or G1/pKFSS1 did not display ﬂuores-
cence reactivity with the CRASP-4 antiserum.
3.4. Binding of Human Serum Proteins by B. garinii
G1/pCRASP-4. Having demonstrated binding of CFHR1,
CFHR2 and CFHR5 to recombinant CRASP-4, we next ex-
aminedwhetherliveG1/pCRASP-4cellsalsobindthehuman
complement regulators. To this end, serum-resistant B.
burgdorferi LW2 (positive control), serum-sensitive B. garinii
G1 (negative control), and transformants G1/pKFSS1 and
G1/pCRASP-4 were incubated in NHS supplemented with
EDTA (to prevent complement activation). After serum
incubation, the ﬁnal wash and elute fractions were separated
by SDS-PAGE and subjected to Western blotting with a poly-
clonal antiserum that recognizes CFH and the CFH-related
proteins CFHR1, CFHR1α,C F H R 1 β, CFHR2, CFHR2α,
and CFHR5 (Figure 4). Serum-resistant B. burgdorferi LW2
bound CFH, CFHR1α,C F H R 1 β,C F H R 2 ,a n dC F H R 2 α.I n
contrast, wild-type strain G1 and transformant G1/pKFSS1
did not bind CFH or any CFH-related proteins. Four promi-
nent bands with apparent masses of 35, 32, 25 and 22kDa
were detected in the last wash and the eluate fraction of
G1/pCRASP-4. Based on their mobilities, the 35 and 32kDa
proteins most likely correspond to the two glycosylated
formsCFHR1αandCFHR1β. The25and22kDabandswere
probably the nonglycosylated and the glycosylated forms of
CFHR2. A barely visible band with an apparent molecular
mass of 55kDa could only be detected in the eluate fraction
of G1/pCRASP-4, which was probably CFHR5. The bands
with molecular masses of 40, 60 and >250kDa seen in the
eluate fractions of all strains represent unspeciﬁc binding of
the antiserum. There was not any indication of binding the
150kDaCFHprotein.Takentogether,CRASP-4producedon
the surface of live Borreliae strongly binds the human serum
proteins CFHR1 and CFHR2, lesser amounts CFHR5 but no
detectable CFH.
3.5.SerumSusceptibilityofB.gariniiProducingSurface-Local-
izedCRASP-4. TodeﬁnetherolesofCFHRsandCRASP-4in
the complement resistance of Borreliae, a growth inhibition
assay was used to examine the ability of transformant G1/
pCRASP-4 to survive in the presence of complement active
NHS (Figure 5). As expected, growth of B. burgdorferi LW2Clinical and Developmental Immunology 7
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Figure 3: Characterization of B. garinii G1 producing CRASP-4. (a) B. garinii G1 and transformed strains G1/pKFSS1 and G1/pCRASP-
4 were characterized by PCR ampliﬁcation using ﬂaB-, aadA-,a n derpC-speciﬁc primers, as listed in Table 1. (b) Synthesis of CRASP-4
by transformed G1 was assessed using ligand aﬃnity blotting. Whole cell lysates (15μg each) of G1, G1/pKFSS1 and G1/pCRASP-4 were
separated by SDS-PAGE, and transferred to nitrocellulose. After incubation with NHS, binding of CFH to CRASP-4 was identiﬁed using a
polyclonalantiserum.Amonoclonalantibody,L411C11,speciﬁcfortheﬂagellinproteinFlaB,wasappliedtoshowequalloadingofborrelial
lysates. (c) Surface localization of CRASP-4 in transformed G1 cells. Spirochetes were incubated with or without proteinase K or trypsin,
respectively, then lysed by sonication, and total proteins were separated by SDS-PAGE. CRASP-4 was identiﬁed by ligand aﬃnity analysis
as described above. Flagellin (FlaB) was detected with MAb L41 1C11 (dilution 1/1000) by Western blotting. (d) Demonstration of surface
expression of CRASP-4 by transformed B. garinii G1, by indirect immunoﬂuoresecence microscopy of intact borrelial cells. Spirochetes were
incubated with rabbit polyclonal anti-ErpA/ErpC antiserum before ﬁxation. Periplasmic FlaB, used as control, was detected by mAb L41
1C11 using ﬁxed and unﬁxed cells. For counterstaining, the DNA-binding dye DAPI was used to identify all bacteria. Slides were visualized
at a magniﬁcation of ×1,000 using an Olympus CX40 ﬂuorescence microscope mounted with a DS-5Mc charge-coupled device camera
(Nikon).
included as control was unaﬀected, as indicated by a contin-
uous decrease of the absorbance values (due to the colour
change of the medium). In contrast, wild-type strain G1,
G1/pKFSS1, and G1/pCRASP-4 survived in heat-inactivated
NHS but not in native NHS. The failure of the CRASP-4
producing transformant to survive suggests that binding of
CFHR1, CFHR2, and CFHR5 is not suﬃcient for mediating
complement resistance.
Next we examined deposition of complement activa-
tions products C3, C6 and the membrane attack complex
(MAC) on the surface of the transformant G1/pCRASP-4, B.
burgdorferi LW2, and B. garinii G1. Following incubation in
NHS, the majority of cells of G1/pCRASP-4 and wild-type
strain G1 displayed strong ﬂuorescence, suggesting that large
amountsofC3,C6,andMACweredepositedontheborrelial
cell surface (Figure 6). In addition, extensive bleb formation,
cell fragmentation, and lack of DAPI staining indicate that
spirochetes were lysed. In contrast, bacteria incubated with
heat-inactivated NHS did not show evidence of complement
deposition (data not shown).8 Clinical and Developmental Immunology
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Figure 5: Serum susceptibility of transformed B. garinii G1. A growth inhibition assay was used to investigate susceptibility to human serum
of B. burgdorferi strain LW2 and B. garinii strains G1 and G1/pCRASP-4. Spirochetes were incubated in either 50% NHS (open triangles)
or 50% heat-inactivated NHS (ﬁlled triangles) over a cultivation period of 9 days at 33◦C, respectively. Color changes were monitored by
measurement of the absorbance at 562/630nm. All experiments were performed three times during which each test was done at least in
triplicate with very similar results. For clarity only data from a representative experiment are shown. Error bars represent ± SD.
Taken together, binding of CFHRs by CRASP-4 produc-
ing spirochetes does not suﬃciently protect spirochetes from
complement-mediated killing.
4. Discussion
To survive in diﬀerent compartments and persistently infect
their potential hosts, Borreliae have developed a variety of
strategies that include overcoming destructive attacks by
host complement. In particular, serum-resistant B. burgdor-
feri, B. afzelii,a n dB. spielmanii isolates bind the human
ﬂuid phase complement regulators CFH and FHL1 that
allow spirochetes to ﬁnely regulate and inhibit complement
activation on their cell surface [6, 7, 51]. In this study,
we extend the characterization of molecular interaction of
CFH/CFHR proteins and show that the infection-associated
CRASP-4/ErpC protein of B. burgdorferi binds the host
complement regulators CFHR1, CFHR2, and CFHR5, and
to some extent CFH. However, CRASP-4 exposed to the
outer surface of viable cells preferentially binds complement
regulators CFHR1α,C F H R 1 β, CFHR2, and CFHR2α.
CFHR1andCFHR5,andlikelyalsoCFHR2,exhibitcom-
plementregulatoryactivities.Thus,recruitmentofthesehost
proteins may help spirochetes to control complement activa-
tion. In agreement with our earlier observations of the inter-
action of CFH with native CRASP-3 and CRASP-5, the data
presented herein showed that CFHR1, CFHR2, and CFHR5
alone or in concert are not suﬃcient to control complement
activation at the borrelial surface. CFHR1 and CFHR2
are major constituents of serum lipoprotein particles that
also contain apolipoprotein A-I, lipopolysaccharide-binding
protein, phospholipids, and ﬁbrinogen [52, 53]. Thus, itClinical and Developmental Immunology 9
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Figure 6: Deposition of complement components C3 and C6, and MAC on the surface of borrelial strains. Deposition of complement
components on B. burgdorferi LW2 (control strain), B. garinii G1 and transformant G1/pCRASP-4 were detected by indirect immuno-
ﬂuorescence microscopy. Spirochetes were incubated with 25% NHS. Bound C3, C6, or MAC was detected using speciﬁc antibodies against
each component plus appropriate Alexa-488-conjugated secondary antibodies. For visualization of intact spirochetes, the DNA-binding dye
DAPI was used. Slides were visualized at a magniﬁcation of ×1,000 and the data were recorded via a DS-5Mc CCD camera (Nikon) mounted
on an Olympus CX40 ﬂuorescence microscope. Panels shown are representative of at least 20 microscope ﬁelds.
could be speculated that Lyme disease Borreliae capture
lipoprotein particles through CFHR1 and CFHR2 to allow
adherence to host epithelial cells and tissues, as has been
described for CFH-coated Streptococcus pneumoniae [54].
Interaction with CFH has previously been reported for
CRASP-4/ErpC and other closely related Erp proteins, for
example, OspE paralogs from B. burgdorferi, B. afzelii, B.
spielmanii, B. garinii, B. lusitaniae, B. turdi, B. tanukii,a n d
B. japonica [3, 6, 11, 12, 33, 35, 37, 38, 43, 51, 55–58]. Here
we demonstrate that recombinant CRASP-4 bound CFH in
ELISA or ligand aﬃnity blot experiments using borrelial
cell lysates (Figures 2 and 3(b)). However, binding of CFH
could not be detected if CRASP-4 was coated onto magnetic
particles or was expressed on the surface of transformed
borrelial cells (Figures 1(a) and 1(b) and Figure 4). Previ-
ous studies using surface plasmon resonance revealed that
CRASP-4incomparisontoCRASP-3andCRASP-5displayed
strong aﬃnity for CFHR1 and the lowest binding aﬃnity
to CFH, suggesting a preferential binding to the smaller
CFHR molecules [38]. CRASP-3 and CRASP-5, when het-
erologously produced in B. garinii G1 or in a high-passaged
mutant strain B313 (a derivative of type strain B. burgdorferi
B31 that carries only one copy of the CRASP-5-encoding
erpA gene), similarly did not bind CFH [31, 39,P .K r a i c z y
unpublished data]. However, we cannot completely exclude
conformational changes of surface-exposed CRASP-4 due to
misfolding in B. garinii. Furthermore, heterologous produc-
tion of the two CFH/FHL1-binding CRASP proteins CspA
or CspZ in B. garinii G1 did not inﬂuence their functional
activity to interact with CFH and FHL1, which might also
argue for correct folding of borrelial proteins in this model
organism [42, and P. Kraiczy unpublished data]. Conceiv-
ably, the stronger aﬃnity of CRASP-4 to CFHR1 and CFHR2
mayalsofavorpreferentialbindingofthesemoleculestobor-
relialcells(Figure4),eventhoughCFHispresentina10-fold
higher concentration in human plasma than both CFHRs
[38, 59]. As demonstrated earlier and in the present study,
the individual CFH/CFHR-binding CRASP proteins (recom-
binant or native) possess diﬀerent relative aﬃnities for CFH,
CFHR1, CFHR2, and CFHR5 [38, 39, 59]. When expressed
on borrelial surfaces,none of those CRASPs bound CFH, but
they did show prominent binding to CFHR1 and CFHR2.
Binding of CFHR5 was more pronounced for CRASP-3 as
compared to CRASP-4 and CRASP-5. Collectively, all three
CRASPs displayed the strongest aﬃnities for CFHR2.
Apparently as a consequence of the inability of CFH
to bind to the microbial surface, bacteria accumulated des-
tructive complement activation products, that is, C3 and
MAC, on their surfaces and were killed (Figures 5 and 6).
Displacement of CFH by CFHR1 or CFHR2, which exhibits
sequence identities of 89 and 61% to the C-terminal SCRs
19 and 20 of CFH, respectively, or improper binding of CFH
to CRASP-4 by other yet unknown factors may have led to
that phenomenon. Once complement is activated, it appears
that the inhibitory activity of CFHR1 on the C5 convertase
and the capacity of CFHR5 (although bound in minuscule
amounts on the bacterial surface) to inactivate C3b can not
completely impede formation and insertion of the MAC, in
particularwhenlargeamountsofC3banddownstreameﬀec-
tor complement components are deposited on the bacterial
membrane (Figure 6). This points to a crucial role of human
CFH and FHL1 in complement resistance of Borreliae.
A CspA-deﬁcient B. burgdorferi strain that carries two
native copies of the erpA gene did not survive in human
serum, indicating that CRASP-5 alone cannot suﬃciently
protect Lyme disease Borreliae from complement-mediated
killing [40, 41]. However, heterologous production of
CRASP-3 and CRASP-5 in the same CspA-deﬁcient strain
signiﬁcantly increased spirochetal survival in the presence of
20% human serum, suggesting that both proteins exhibit a
synergistic eﬀect on complement resistance [43]. However,
mutant strain B313, which lacks CRASP-1, -2, and -3, but
produces native CRASP-4 and -5, did not bind CFH and was
highly susceptible to complement-mediated killing by 50%10 Clinical and Developmental Immunology
human serum (data not shown). Mutant strain B313 is a
clonalmutantofB31thatlacksallthatstrainplasmidsexcept
cp32-1, cp32-2, cp32-3 cp32-4, cp26, and lp17 and therefore
is unable to produce a variety of outer surface proteins,
such as the major surface proteins OspA and OspB [60, 61].
The absence of a high number of outer surface proteins
might inﬂuences the entire membrane composition and,
thus, might eﬀects the functional properties of these CFHR-
binding CRASPs in the mutant strain B313. Conceivably,
other proteins that are absent in B313 might serve as
bystanderstopromoteoptimalbindingofthelargeCFHpro-
tein (which forms dimeric or oligomeric complexes in solu-
tion at physiological concentrations) to CRASP-3, CRASP-4,
and CRASP-5.
Taken together, we identiﬁed complement proteins
CFHR2 and CFHR5 as novel ligands for the infection-asso-
ciated CRASP-4/ErpC protein of B. burgdorferi.C R A S P - 4
exposed to the borrelial surface preferentially binds CFHR1
and CFHR2 while binding of CFH and CFHR5 could only be
detected under artiﬁcial experimental conditions. Although
binding of CFHRs appears to be not necessary for comple-
ment resistance, the impact of these particular host proteins
for immune evasion and pathogenesis of Borreliae warrants
further investigations.
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